Optipeg-A
Rx180 mcg/0.5 ml • SC Injection
Indications & Uses
Optipeg-A is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Chronic hepatitis C: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thighChronic hepatitis B: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thighHepatitis C Genotype 1 & 4: Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 48 weeks; Celbarin: <75 kg= (400+0+600) mg, >75 kg= (600+0+600) mg. Hepatitis C Genotype 2 & 3: Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 24 weeks; Celbarin: (400+0+400) mg. Pediatric Use: The safety and effectiveness of Pegferon®, alone or in combination with Ribavirin in patients below the age of 5 years have not been established.
Side Effects
Depression, suicide, relapse of drug abuse and bacterial infection Flu like symptoms: Fatigue, pyrexia, Gastrointestinal: Nausea/Vomiting, diarrhea, abdominal pain Metabolic and Nutritional: Anorexia Musculoskeletal: Myalgia, arthralgia Neurological: Headache, dizziness, insomnia Psychiatric reactions: Irritability, anxiety Injection site reaction, skin problems, hair loss Endocrine: Hypothyroidism
Cautions & Contraindications
Warnings & Precautions
Patients who have failed alpha interferon treatment with or without ribavirin Liver or other organ transplant recipients Hepatitis B patients coinfected with HCV or HIV Hepatitis C patients coinfected with HBV or coinfected with HIV with a CD4+ cell count < 100 cells/µL Caution should be exercised in initiating treatment in any patient with baseline risk of severe anemia
Contraindications
Hypersensitivity to any component of the product Autoimmune hepatitis Hepatic decompensation in cirrhotic patients before or during treatment Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients co infected with HIV during or before treatment Neonate or infants.